Back to top
more

Teva Pharmaceutical Industries (TEVA)

(Delayed Data from NYSE)

$18.45 USD

18.45
7,100,133

+0.01 (0.05%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $18.45 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 20% (49 out of 250)

Industry: Medical - Generic Drugs

Better trading starts here.

Zacks News

Mylan (MYL) to Get CRL Again for Generic Advair from FDA

Mylan (MYL) suffers another setback with its ANDA for Advair as the FDA refuses to approve the same, due to minor deficiencies.

    Abbvie/Roche's Leukemia Drugs Combination Gets FDA Approval

    AbbVie (ABBV) and Roche's (RHHBY) cancer drugs, Venclexta and Rituxan receive approval for combination use in second-line chronic lymphocytic leukemia.

      Nektar (NKTR) Seeks Approval for Analgesic Opioid Candidate

      Nektar (NKTR) submits NDA to the FDA seeking approval of its analgesic opioid candidate, NKTR-181, for the treatment of chronic low back pain.

        Teva (TEVA) Stock Up 17% YTD After a Dismal 2017: Here's Why

        Teva's (TEVA) shares gain 17% in 2018 so far after declining sharply in 2017.

          FDA Confirms September Action Date for Teva's Migraine Drug

          Teva (TEVA) confirms that FDA has extended the goal date of the Biologics License Application (BLA) for fremanezumab to September from mid-June.

            Should You Hold Momenta (MNTA) Stock in Your Portfolio?

            Momenta (MNTA) is conducting a strategic review of its ongoing operations as revenues from Glatopa continue to decline.

              Amgen's Migraine Drug Aimovig Gets FDA Approval, Shares Up

              Amgen's (AMGN) preventive treatment for migraine, Aimovig, gets approval in the United States.

                Company News For May 17, 2018

                Companies In The News are: FOXA,IQV,ABAX,ZTS,TEVA,BRK.B

                  Eli Lilly's Cluster Headache Candidate Succeeds in Phase III

                  Eli Lilly's (LLY) galcanezumab meets the primary endpoint in a late-stage study evaluating it for the prevention of episodic cluster headache.

                    Teva Stock Up 5% as Buffett's Berkshire Raises Stake in Q1

                    Teva's (TEVA) shares gain 5% after Warren Buffett's Berkshire Hathaway reveals an increased stake in the company.

                      Novartis Multiple Sclerosis Drug Gets FDA Nod for Adolescents

                      The FDA approves Novartis' (NVS) multiple sclerosis drug Gilenya for the treatment of children and adolescents aged between 10 and 18.

                        AstraZeneca's (AZN) Asthma Drug Fasenra Fails in COPD Study

                        AstraZeneca's (AZN) asthma drug Fasenra (benralizumab) fails to meet the primary endpoint in a late-stage study evaluating it for a new indication - COPD.

                          BioDelivery (BDSI) Q1 Earnings and Sales Beat Estimates

                          BioDelivery Sciences' (BDSI) reports narrower-than-expected loss in Q1. Sales marginally beat the consensus mark.

                            Ekta Bagri headshot

                            Mylan (MYL) Q1 Earnings Lag on Weak North America Sales

                            Mylan's first-quarter results were dismal with both earnings and sales missing expectations as challenges in North America persist.

                              Momenta (MNTA) Incurs Wider Y/Y Loss, Glatopa Sales Decline

                              Momenta reported a wider year-over-year loss in the first quarter. Sales of Glatopa declined due to competition from Mylan.

                                Mylan (MYL) to Report Q1 Earnings: What's in the Offing?

                                Investors are exepcted to focus on the performance of EpiPen, newly launched drugs and the progress of the company's biosimilars pipeline when Mylan (MYL) reports results for the Q1.

                                  Teva (TEVA) Stock Dips Despite Q1 Earnings & Sales Beat

                                  Teva's (TEVA) shares dip despite first-quarter earnings and sales beat. The company raises its 2018 sales and earnings outlook.

                                    Kinjel Shah headshot

                                    Teva (TEVA) Up on Q1 Earnings & Sales Beat, Rise in Guidance

                                    Teva's (TEVA) first-quarter earnings and sales beat expectations. The company raises its 2018 sales and earnings outlook. Stock up in pre-market trading.

                                      Teva (TEVA) to Report Q1 Earnings: What's in the Cards?

                                      Teva's (TEVA) Generics segment sales are likely to be weak due to increased pricing erosion while loss of exclusivity of key drugs like Copaxone is likely to hurt sales of the Specialty segment.

                                        Novartis (NVS) Reports Encouraging Data on MS Candidate

                                        Novartis (NVS) announces encouraging results from a phase III study, EXPAND, on siponimod (BAF312) in patients with secondary progressive multiple sclerosis.

                                          Amgen's Aimovig Reduces Episodic Migraine in 30% Patients

                                          Amgen (AMGN) releases full data from the phase IIIb trial, evaluating the efficacy and safety of Aimovig on patients suffering episodic migraine with multiple treatment failures.

                                            Mylan Inks Deal with Mapi Pharma for Multiple Sclerosis Drug

                                            Mylan (MYL) has inked a deal with Israel based Mapi Pharma to acquire its multiple sclerosis candidate.

                                              AbbVie (ABBV) Stock Falls on Weak Lung Cancer Study Outcome

                                              AbbVie's (ABBV) key lung cancer candidate, Rova-T falls short in a phase II study. AbbVie will not seek accelerated approval of Rova-T in the third-line setting

                                                BioDelivery (BDSI) Q4 Loss Wider-Than-Expected, Sales Up Y/Y

                                                BioDelivery (BDSI) reports wider-than-expected loss in Q4. However, revenues surpass estimates and increase substantially year over year.

                                                  Zacks Industry Outlook Highlights: AstraZeneca, Bayer, Dr. Reddy's Laboratories, Teva Pharmaceuticals and Adamas Pharmaceuticals

                                                  Zacks Industry Outlook Highlights: AstraZeneca, Bayer, Dr. Reddy's Laboratories, Teva Pharmaceuticals and Adamas Pharmaceuticals